Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Nevirapine
Drug ID BADD_D01557
Description A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
Indications and Usage For use in combination with other antiretroviral drugs in the ongoing treatment of HIV-1 infection.
Marketing Status approved
ATC Code J05AG01
DrugBank ID DB00238
KEGG ID D00435
MeSH ID D019829
PubChem ID 4463
TTD Drug ID D0O2EM
NDC Product Code 53104-7546; 70159-002; 65862-027; 0378-4050; 64380-709; 65862-932; 65862-933; 31722-505; 65862-057; 68554-0044; 33342-004; 0597-0047; 64220-102; 0378-4890; 65162-209; 33342-238; 42571-131
UNII 99DK7FVK1H
Synonyms Nevirapine | Nevirapine Hemihydrate | Hemihydrate, Nevirapine | Viramune | BI-RG-587 | BI RG 587 | BIRG587
Chemical Information
Molecular Formula C15H14N4O
CAS Registry Number 129618-40-2
SMILES CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neutropenia01.02.03.004---
Neutrophil count13.01.06.046---
Oedema08.01.07.006; 14.05.06.010---
Oligohydramnios18.05.01.0010.002652%-
Opportunistic infection11.01.08.007---
Osteonecrosis15.02.04.007; 24.04.05.0040.003978%
Pain08.01.08.004--
Pancreatitis07.18.01.001--
Pancreatitis acute07.18.01.0020.003978%-
Paraesthesia17.02.06.005; 23.03.03.094--
Peripheral sensory neuropathy17.09.03.0050.003978%
Photophobia06.01.01.004; 17.17.02.0060.002652%
Platelet count13.01.04.011---
Premature baby18.04.02.0010.005304%-
Pruritus23.03.12.001--
Pyrexia08.05.02.0030.015912%
Rash23.03.13.0010.013791%-
Rash erythematous23.03.13.029---
Rash maculo-papular23.03.13.0040.002652%
Rash papular23.03.13.017---
Renal failure20.01.03.0050.007956%-
Respiratory distress22.02.01.0120.002652%-
Rhabdomyolysis15.05.05.002--
Skin disorder23.03.03.007---
Skin exfoliation23.03.07.003---
Somnolence17.02.04.006; 19.02.05.003--
Stevens-Johnson syndrome10.01.01.045; 11.07.01.005; 12.03.01.014; 23.03.01.0070.009282%
Stillbirth08.04.01.006; 18.01.02.0020.003978%-
Surgery25.01.02.003---
Swelling face08.01.03.100; 10.01.05.018; 23.04.01.0180.005834%-
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene